Larimar Therapeutics, Inc. — Director's Dealing 2017

Dec 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2017-12-29

Reporting Person: Hatfield Jeffrey S. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-29	Stock Option (Right to Buy)	$3.40	A	1100000	Acquired	2027-10-09	Common Stock (1100000)	Direct

Footnotes

F1: This option was granted on October 9, 2017, subject to vesting based on the Issuer's stock price appreciation and certain financial performance goals. The financial performance goals were waived on December 29, 2017 and therefore the option is deemed a reportable derivative security as of such date.

F2: The option vests and becomes exercisable based on the Issuer's common stock price during the two years after the first anniversary of the date of grant as follows: 25% of shares subject to the option vest after the stock price is equal to or greater than $10.00 per share for 20 consecutive trading days; and an additional 6.25% of the shares subject to the option vest for every additional $2.50 in stock price above $10.00 per share for 20 consecutive trading days. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4).